'Original antigenic sin' at the center of researchers' model addressing age-specific influenza immunity

October 11, 2012

(Medical Xpress)—Mathematicians are helping to build a better picture of how populations develop immunity to flu and which groups are most at risk of getting – and transmitting – infection each year.

The adage 'what doesn't kill you makes you stronger' may ring true for certain – those where repeated exposure to the pathogen progressively builds population immunity – but not for . When scientists investigated age-specific immunity to after the 2009 , a curious pattern emerged. Antibodies against seasonal flu appear to peak in school-age children, drop in and rise again in the over 65s.

Now in Cambridge have developed a model that explains this little-understood pattern, and in so-doing are helping to build a better picture of how flu might be controlled. At the heart of their model is the concept of 'original antigenic sin', a phenomenon first identified in the 1960s by American Thomas Francis that describes how the body's immune system, in effect, takes short cuts.

Rather than generating a specific antibody response every time a new pathogen is encountered, the immune system may instead reproduce a previous response to something similar (the 'original antigenic sin') it has seen before. What this means for immunity is that it's not just the infections we've had in the past but the order in which we've had them that could be important for how protected we are against a disease.

Dr Julia Gog and PhD student Adam Kucharski at the Department of Applied Mathematics and believe that the strikingly characteristic profile of immunity to influenza can be explained in these terms, and they've built a to test it.

Understanding how immunity develops in a population is crucial for developing a robust public health defence, especially for a pathogen like , which the UK government's latest National Risk Register has listed as the most likely risk to have the highest impact in the next five years.

Yet, modelling the dynamics of influenza on population immunity is no straightforward exercise, as Gog explained: "The evolving nature of the virus – necessitating an annual race to identify an appropriate vaccine – means that individuals can be exposed to many different strains over a lifetime. And for every new strain that appears, the number of possible infection histories a person could have had doubles. To build a model, mathematicians need to keep track of millions, if not billions, of possible combinations of infections."

According to Gog and Kucharski's model, the trick is to reconstruct the combinations of past exposures from the probabilities of having seen each particular strain. There is a catch, however. Individuals who have been exposed to one particular strain are more likely to have been exposed to other strains; this is because individuals who have previously been exposed are more likely to be old than young. The model therefore handles each age group separately: individuals who are the same age will have lived through the same series of epidemics, which means that past exposures will be independent.

Their model has enabled them to explain the distinctive pattern of age-specific immunity for flu. Immunity increases initially, peaking in school-age children, then decreases as previous exposures prevent new antibodies being made. Only when the strain evolves 'out of reach' of the original antigenic sin are new antibodies generated in later middle age. In the elderly, complete freedom from original antigenic sin, along with vaccination programmes, leads to another increase in immunity.

But what does this mean for disease control and identifying risk? "There could be gaps in immunity because less-effective immune responses are being generated as a result of original antigenic sin," explained Kucharski. "Over time, certain age groups may develop 'blind spots' in their antibody profile. We are building 'gap maps' to understand how often this happens. Moreover, the view that severe epidemics only arise when the virus has evolved significantly may be oversimplified. They could also arise if there are individuals whose immune response is ineffective because of original antigenic sin, which would explain why unassuming flu strains occasionally cause large outbreaks."

Explore further: Flu vaccine research: overcoming 'original sin'

Related Stories

Flu vaccine research: overcoming 'original sin'

August 13, 2012

(Medical Xpress) -- Scientists studying flu vaccines have identified ways to overcome an obstacle called "original antigenic sin," which can impair immune responses to new flu strains.

Recommended for you

Zika virus infection alters human and viral RNA

October 20, 2016

Researchers at University of California San Diego School of Medicine have discovered that Zika virus infection leads to modifications of both viral and human genetic material. These modifications—chemical tags known as ...

Food-poisoning bacteria may be behind Crohn's disease

October 19, 2016

People who retain a particular bacterium in their gut after a bout of food poisoning may be at an increased risk of developing Crohn's disease later in life, according to a new study led by researchers at McMaster University.

Neurodevelopmental model of Zika may provide rapid answers

October 19, 2016

A newly published study from researchers working in collaboration with the Regenerative Bioscience Center at the University of Georgia demonstrates fetal death and brain damage in early chick embryos similar to microcephaly—a ...

Scientists uncover new facets of Zika-related birth defects

October 17, 2016

In a study that could one day help eliminate the tragic birth defects caused by Zika virus, scientists from the Florida campus of The Scripps Research Institute (TSRI) have elucidated how the virus attacks the brains of newborns, ...

Ebola drug ZMapp may help, but is not a miracle cure

October 13, 2016

ZMapp, once touted as a miraculous "secret serum" against the deadly Ebola virus, has shown some success but fell short of the bar for effectiveness in a clinical trial, researchers said Wednesday.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.